Inhibrx Biosciences Statistics
Share Statistics
Inhibrx Biosciences has 14.48M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 14.48M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 72.16% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 23,042 |
| FTD / Avg. Volume | 20.72% |
Short Selling Information
The latest short interest is 729.92K, so 5.04% of the outstanding
shares have been sold short.
| Short Interest | 729.92K |
| Short % of Shares Out | 5.04% |
| Short % of Float | 6.95% |
| Short Ratio (days to cover) | 8.35 |
Valuation Ratios
The PE ratio is 0.13 and the forward
PE ratio is -1.54.
Inhibrx Biosciences's PEG ratio is
0.
| PE Ratio | 0.13 |
| Forward PE | -1.54 |
| PS Ratio | 1114.64 |
| Forward PS | 0.8 |
| PB Ratio | 1.67 |
| P/FCF Ratio | -1.13 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Inhibrx Biosciences has an Enterprise Value (EV) of 78.38M.
| EV / Sales | 391.9 |
| EV / EBITDA | 0.05 |
| EV / EBIT | -0.4 |
| EV / FCF | -0.4 |
Financial Position
The company has a current ratio of 3.94,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.94 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -24.57 |
Financial Efficiency
Return on Equity is 1263.3% and Return on Invested Capital is -234.02%.
| Return on Equity | 1263.3% |
| Return on Assets | 933.56% |
| Return on Invested Capital | -234.02% |
| Revenue Per Employee | $1,282.05 |
| Profits Per Employee | $10,817,769.23 |
| Employee Count | 156 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.02% in the
last 52 weeks. The beta is -0.94, so Inhibrx Biosciences's
price volatility has been lower than the market average.
| Beta | -0.94 |
| 52-Week Price Change | -67.02% |
| 50-Day Moving Average | 12.84 |
| 200-Day Moving Average | 14.04 |
| Relative Strength Index (RSI) | 41.17 |
| Average Volume (20 Days) | 111,212 |
Income Statement
In the last 12 months, Inhibrx Biosciences had revenue of 200K
and earned 1.69B
in profits. Earnings per share was 114.01.
| Revenue | 200K |
| Gross Profit | -2.08M |
| Operating Income | -331.45M |
| Net Income | 1.69B |
| EBITDA | 1.7B |
| EBIT | 1.7B |
| Earnings Per Share (EPS) | 114.01 |
Full Income StatementBalance Sheet
The company has 152.6M in cash and 8.05M in
debt, giving a net cash position of 144.55M.
| Cash & Cash Equivalents | 152.6M |
| Total Debt | 8.05M |
| Net Cash | 144.55M |
| Retained Earnings | -106.13M |
| Total Assets | 180.77M |
| Working Capital | 119.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -194.41M
and capital expenditures -2.6M, giving a free cash flow of -197.01M.
| Operating Cash Flow | -194.41M |
| Capital Expenditures | -2.6M |
| Free Cash Flow | -197.01M |
| FCF Per Share | -13.61 |
Full Cash Flow StatementMargins
Gross margin is -1042.5%, with operating and profit margins of -165724% and 843786%.
| Gross Margin | -1042.5% |
| Operating Margin | -165724% |
| Pretax Margin | 843787% |
| Profit Margin | 843786% |
| EBITDA Margin | 851675% |
| EBIT Margin | -165724% |
| FCF Margin | -98503% |
